AlphAIAlphAI — Financial news for AI agents
benzinga.comAUG 202 min read$AUPH

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), with Teva agreeing to not launch its generic voclosporin product until Dec. 7, 2036. Aurinia's Lupkynis is the first FDA-approved oral therapy for lupus nephritis. AUPH shares rose 2.66% premarket to $16.60, trading above its 20-day SMA of $15.31.

Original reporting
benzinga.com
Published Aug 20, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Aurinia Pharmaceuticals — source image
Source · benzinga.com
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

The settlement is a positive catalyst, reducing near-term revenue dilution risk.

02

Market read

Legal settlement news provides a fresh, material catalyst for AUPH, influencing trader decisions.

03

What to watch

Potential regulatory scrutiny of the settlement terms could introduce risk.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Aurinia's Lupkynis is the only approved oral therapy for lupus nephritis; the settlement delays generic competition.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

Aurinia settled a patent dispute with Teva, securing enforceability of its voclosporin patents and delaying generic entry until Dec 7, 2036.

Expected impact

Potential upside of 5-10% as investors price in delayed generic launch.

Evidence & confidence

Legal protection of patents extends market exclusivity, a material catalyst for a biotech with limited pipeline.

Market effects

Sector

May boost confidence in other biotech firms with pending patent litigations.

Regional

Limited to US biotech sector.

Global

Minimal beyond niche pharma investors.

Counterpoint

What could challenge this read

If Teva successfully challenges the patents later, generic entry could occur sooner, negating the upside.

Key entities

  • Company
    Aurinia Pharmaceuticals

    Biopharma developing Lupkynis (voclosporin).

  • Company
    Teva Pharmaceutical Industries

    Generic drug manufacturer seeking to launch a generic version of voclosporin.

Read at source← All news

Related articles

SEP 17
$AUPHMed

Aurinia Stock Jumps After Earnings Beat And Pipeline Progress

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M and net income of $37.4M, with LUPKYNIS sales at $79.4M. The company initiated new clinical studies for aritinercept. Analysts forecast revenue of $453.5M and earnings of $169.9M by 2029, with a 7% upside potential. The stock rose on earnings beat and pipeline progress.

simplywall.st2 min
SEP 16
$AUPHMed

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.

yahoo.com2 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min